TRTP-30X

TRTP-30X is an investigational regenerative medicine candidate being developed by Cell In Cells, a South Korean biotechnology firm. It is based on the company's Tissue-specific Regenerative Therapeutic Platform (TRTP), which employs a "Cell-in-Cells" (CiC) technology designed to deliver functional organelles or other cellular materials into target cells. This approach, termed "cell-to-cell transformation," is intended to restore the physiological function of damaged or aging cells by enhancing their regenerative capacity. While specific clinical details for the 30X designation are limited, the 300-series of the TRTP pipeline is generally focused on musculoskeletal regeneration, with related candidates such as TRTP-301 targeting indications like osteoarthritis.